Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAVA-LTE long-term safety extension of mavacamten in hypertrophic cardiomyopathy
2022-502858-14-00Phase 3Completed
- Sponsor
- MyoKardia
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, open-label, single-arm trial of mavacamten in hypertrophic cardiomyopathy (HCM), sponsored by MyoKardia. Primary endpoints: Incidence of major adverse cardiac events, Incidence of hospitalizations and 8 more. Started Oct 2023; status: completed.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on 2022-502858-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502858-14-00.